AU · rank #1 · 2026-09-04
PGEN
NASDAQ · $2.46B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 3.623 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.48 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $24,662 across 1 unique buyers. | 2.409 |
| Analyst upside Consensus target $14.50 | +103.1% |
| Momentum acceleration 3-month minus 12-month momentum. | +85.30% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.75 |
| Gross margin TTM | +53.0% |
| 52w high | $7.72 |
| Market cap (USD) | $2.46B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Precigen is a commercial-stage gene therapy company whose entire revenue base rests on PAPZIMEOS, the first-and-only FDA-approved treatment for recurrent respiratory papillomatosis, which just delivered its first profitable quarter in Q2 2026.
Rationale
The 103% analyst upside, 100% revision agreement, a 475% earnings surprise, and sequential PAPZIMEOS revenue more than doubling in Q2 directly reinforce the analyst_upside strategy's logic that consensus targets are lagging a genuine commercial inflection.
Material risks
- 1Single-product concentration means any safety signal, reimbursement denial, or payer pushback on PAPZIMEOS pricing would collapse the entire revenue thesis with no pipeline backstop to cushion the blow.
- 2Coverage by only 3 analysts with high target dispersion (48%) and zero net upgrades in 90 days suggests the upside case is thinly followed and the 103% implied upside may reflect stale or outlier targets rather than broad institutional conviction.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.